Detalhe da pesquisa
1.
Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
Am Heart J
; 265: 83-91, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271359
2.
A Multimodal Cardioprotection Strategy During Cardiac Surgery: The ProCCard Study.
J Cardiothorac Vasc Anesth
; 37(8): 1368-1376, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202231
3.
Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.
N Engl J Med
; 379(24): 2297-2306, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30145927
4.
Multimodal cardioprotective strategy in cardiac surgery (the ProCCard trial): Study protocol for a multicenter randomized controlled trial.
Trials
; 20(1): 560, 2019 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511041
5.
Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years.
Eur J Heart Fail
; 21(12): 1619-1627, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31476260
6.
Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA® coding in the MITRA-FR study.
Eur J Heart Fail
; 24(2): 396-398, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907629
7.
ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
MAbs
; 6(3): 794-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24481211
8.
Visibility of retractions: a cross-sectional one-year study.
BMC Res Notes
; 6: 238, 2013 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782596
9.
[Retractions due to errors and frauds]. / Rétractations pour erreur et pour fraude.
Presse Med
; 41(9 Pt 1): 847-52, 2012 Sep.
Artigo
em Francês
| MEDLINE | ID: mdl-22841376
10.
Ex vivo study of bevacizumab transport through porcine nasal mucosa.
Eur J Pharm Biopharm
; 80(2): 465-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22120685